About the job
ABOUT US
In the U.S., over 9 million individuals are immunocompromised. Among these, nearly half a million are at heightened risk of severe COVID-19, including patients who have undergone stem cell and solid organ transplants, as well as those battling hematologic cancers.
At Invivyd, Inc., we are committed to addressing these challenges daily, working towards delivering robust protection against serious viral infectious diseases, starting with SARS-CoV-2. Our innovative and proprietary integrated technology platform is unparalleled in the industry, enabling us to assess, monitor, develop, and adapt strategies to create best-in-class antibodies.
In March 2024, Invivyd garnered emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) within our pipeline of forward-thinking antibody candidates.
By October 2025, the FDA approved our Investigational New Drug (IND) application, facilitating progression for the REVOLUTION clinical program—our initiative to develop VYD2311, a monoclonal antibody alternative to vaccines aimed at preventing COVID-19.
Join us in making a meaningful impact. Join Invivyd.
Location: Central (Remote Position)

